In tumor cells, RIG-I activation has been shown to induce immunogenic cell death, which promotes cross-presentation of tumor-associated antigens through bystander DCs and augments the efficacy of CTLA-4 checkpoint blockade [27–29]. This evidence concerns the gene RIGI and neoplasm.